Affordability and availability of off-patent drugs in the United States—the case for importing from abroad: observational study

Abstract Objectives To evaluate whether off-patent prescription drugs at risk of sudden price increases or shortages in the United States are available from independent manufacturers approved in other well regulated settings around the world. Design Observational study. Setting Off-patent drugs in the USA and approved by the Food and Drug Administration, up to 10 April 2017. Study cohort Novel tablet or capsule prescription drugs approved by the FDA since 1939 that were no longer protected by patents or other market exclusivity and had up to three generic versions. Main outcome measures Number of additional manufacturers that had obtained approval from any of seven non-US regulators with similar standards (European Medicines Agency (European Union), HealthCanada (Canada), Therapeutic Goods Association (Australia), Medsafe (New Zealand), Swissmedic (Switzerland), Medicines Control Council (South Africa), and the Israel Health Ministry). Association with drug characteristics including US orphan drug designation for drugs treating rare diseases, World Health Organization essential medicine designation, treatment area, drug product complexity (that is, with attributes that could complicate establishing bioequivalence or manufacturing), and total Medicaid spending in 2015. Results Of 170 eligible study drugs, more than half (109, 64%) had at least one manufacturer approved by a non-US regulator and 32 (19%) had four or more. Among 44 (26%) drugs with no FDA approved generic versions, 21 (48%) were available from at least one manufacturer approved by one of the seven non-US regulators, and two (5%) by four or more manufacturers. Across all drugs and regulators (including the FDA), 66 (39%) drugs were available from four or more total manufacturers. Of 109 drugs with at least one non-US regulator approved manufacturer, 12 (11%) were approved for patients with rare diseases and 29 (27%) were WHO designated essential medicines; only 12 (11%) were complex products that might be more complicated to import. The highest numbers of drugs were indicated for treating cardiovascular diseases, diabetes, or hyperlipidemia (19, 17%); psychiatric disease (16, 15%); and infectious diseases (15, 14%). In 2015, Medicaid alone spent nearly US$700m (£508m; €570m) on generic drugs without adequate US competition that could have had a manufacturer approved by non-US peer regulatory agencies. Conclusion In this study, more than half the off-patent drugs with no generic competition in the USA had at least one independent manufacturer approved by a non-US peer regulatory agency; slightly fewer than half had four or more total manufacturers. Facilitating US patient access to such manufacturers could help sustain affordable access to essential off-patent drugs.

[1]  Gerrit Borchard,et al.  Equivalence of complex drug products: advances in and challenges for current regulatory frameworks , 2017, Annals of the New York Academy of Sciences.

[2]  F. Andersen.  High Generic Drug Prices and Market Competition: A Retrospective Cohort Study: Dave CV, Kesslheim AS, Fox ER, et al. Ann Intern Med. 2017;167(3):145-8 , 2017 .

[3]  S. Simoens,et al.  Clinical, Economic and Policy Implications of Drug Shortages in the European Union , 2017, Applied Health Economics and Health Policy.

[4]  A. Kesselheim,et al.  The Price of Crossing the Border for Medications. , 2017, New England Journal of Medicine.

[5]  A. Kesselheim,et al.  High Generic Drug Prices and Market Competition , 2017, Annals of Internal Medicine.

[6]  J. Ross,et al.  Assessing the potential clinical impact of reciprocal drug approval legislation on access to novel therapeutics in the USA: a cohort study , 2017, BMJ Open.

[7]  A. Kesselheim,et al.  Generic Drug Approvals Since the 1984 Hatch-Waxman Act. , 2016, JAMA internal medicine.

[8]  Robin Cooper Feldman,et al.  Database from Empirical Evidence of Drug Pricing Games - A Citizen's Pathway Gone Astray , 2016 .

[9]  A. Kesselheim,et al.  The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform. , 2016, JAMA.

[10]  J. Ross.  Therapeutic Substitution-Should It Be Systematic or Automatic? , 2016, JAMA Internal Medicine.

[11]  E. Campbell,et al.  Variations in Patients' Perceptions and Use of Generic Drugs: Results of a National Survey , 2016, Journal of General Internal Medicine.

[12]  G. Anderson,et al.  Role of the FDA in Affordability of Off-Patent Pharmaceuticals. , 2016, JAMA.

[13]  K. Schulman,et al.  Options to Promote Competitive Generics Markets in the United States. , 2015, Journal of the American Medical Association (JAMA).

[14]  D. Niakas,et al.  Greek Physicians' Perceptions on Generic Drugs in the Era of Austerity , 2015, Scientifica.

[15]  C. Barbui,et al.  Adherence to generic v. brand antidepressant treatment and the key role of health system factors , 2014, Epidemiology and Psychiatric Sciences.

[16]  T. Brennan,et al.  Comparative Effectiveness of Generic and Brand-Name Statins on Patient Outcomes , 2014, Annals of Internal Medicine.

[17]  Bacchus Barua,et al.  The Case for Mutual Recognition of Drug Approvals , 2013 .

[18]  C. L. Ventola,et al.  The drug shortage crisis in the United States: causes, impact, and management strategies. , 2011, P & T : a peer-reviewed journal for formulary management.

[19]  A. Kesselheim,et al.  Seizure Outcomes Following the Use of Generic versus Brand-Name Antiepileptic Drugs , 2010, Drugs.

[20]  Susan L Ettner,et al.  The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions. , 2006, Archives of internal medicine.